2026年11月4日星期三
M
Panorama Universal
Noticias globales
Mitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaMitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Fuente 柳叶刀 LancetHace 11 días
Resumen del contenido

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Este sitio solo proporciona títulos e índices de resúmenes; el contenido completo y los derechos de autor pertenecen al publicador original. Haga clic en el enlace original para leerlo.

Ir al texto original
Canal al que pertenece
Salud
Región a la que pertenece
Reino Unido
Idioma original
English
Número de entrada
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Panorama Universal